5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) – Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “5′
Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) –
Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s
offering.

5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5)
pipeline target constitutes close to 22 molecules. Out of which
approximately 19 molecules are developed by companies and the remaining
by universities/institutes. This report outlays comprehensive
information on the 5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E
or EC 3.1.3.5) targeted therapeutics, complete with analysis by
indications, stage of development, mechanism of action (MoA), route of
administration (RoA) and molecule type.

5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) –
5′-Nucleotidase (5NT) is an intrinsic membrane glycoprotein that is
present as an enzyme in a wide variety of mammalian cells. It catalyzes
the phosphorylytic cleavage of 5′ nucleotides. The molecules developed
by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and
Discovery stages are 3, 3, 1, 6 and 6 respectively. Similarly, the
universities portfolio in Preclinical and Discovery stages comprises 2
and 1 molecules, respectively.

This report also reviews key players involved in 5′ Nucleotidase (Ecto
5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics
development with respective active and dormant or discontinued projects.
Driven by data and information sourced from proprietary databases,
company/university websites, clinical trial registries, conferences, SEC
filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources.

Scope

• The report provides a snapshot of the global therapeutic landscape for
  5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5)
• The report reviews 5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or
  NT5E or EC 3.1.3.5) targeted therapeutics under development by
  companies and universities/research institutes based on information
  derived from company and industry-specific sources
• The report covers pipeline products based on various stages of
  development ranging from pre-registration till discovery and
  undisclosed stages
• The report features descriptive drug profiles for the pipeline
  products which includes, product description, descriptive MoA, R&D
  brief, licensing and collaboration details & other developmental
  activities
• The report reviews key players involved in 5′ Nucleotidase (Ecto 5′
  Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics and
  enlists all their major and minor projects
• The report assesses 5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or
  NT5E or EC 3.1.3.5) targeted therapeutics based on mechanism of action
  (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline
  projects
• The report reviews latest news and deals related to 5′ Nucleotidase
  (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted
  therapeutics

Reasons to buy

• Gain strategically significant competitor information, analysis, and
  insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio
  and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for
  5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5)
• Identify the use of drugs for target identification and drug
  repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of
  leading companies
• Plan mergers and acquisitions effectively by identifying key players
  and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding 5′
  Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5)
  development landscape
• Develop and design in-licensing and out-licensing strategies by
  identifying prospective partners with the most attractive projects to
  enhance and expand business potential and scope

Companies Mentioned

• Arcus Biosciences Inc
• Bristol-Myers Squibb Co
• Calithera Biosciences Inc
• Corvus Pharmaceuticals Inc
• Evotec AG
• I-Mab Biopharma Co Ltd
• Innate Pharma SA
• InteRNA Technologies BV
• MedImmune LLC
• Novartis AG
• Oric Pharmaceuticals Inc
• Peloton Therapeutics Inc
• Selvita SA

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/w7r0cv

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Oncology
Drugs, Enzymes